Stock Price Forecast

July 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sierra Oncology Inc chart...

About the Company

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

CEO

Stephen Dilly

Exchange

NASDAQ

Website

www.sierraoncology.com

$0M

Total Revenue

69

Employees

$1B

Market Capitalization

-8.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SRRA News

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

1y ago, source: pharmaphorum

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.

Angie You's Net Worth

19d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Sierra Oncology, Inc., Oric Pharmaceuticals, Inc., and RayzeBio, Inc.. Attention insiders: Dive deeper into market ...

Bakker Juliet Tammenoms's Net Worth

3d ago, source: Benzinga.com

Who is Bakker Juliet Tammenoms? Bakker Juliet Tammenoms has an estimated net worth of $533 Million. This is based on reported shares across multiple companies, which include CORCEPT THERAPEUTICS ...

Oncology Drugs - Sierra Leone

5mon ago, source: Statista

The projected revenue for the Oncology Drugs market in Sierra Leone is expected to reach US$10.32m by 2024. It is estimated that the market will experience an annual growth rate (CAGR 2024-2028 ...

Pyxis Oncology Inc PYXS

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

AKUMIN ANNOUNCES PARTNERSHIP WITH NORTHERN NEVADA SIERRA MEDICAL CENTER FOR RADIATION ONCOLOGY SERVICES

27d ago, source: Yahoo Finance

PLANTATION, Fla., Feb. 21, 2024 /PRNewswire/ - Akumin Inc., a national provider of outpatient radiology and oncology services, and Northern Nevada Sierra Medical Center (SMC) today announced a new ...

IKNA Ikena Oncology, Inc.

3d ago, source: Seeking Alpha

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the ...

Glaxo on the hunt for more takeover targets

10mon ago, source: Hosted on MSN

The takeover of Bellus also followed the purchase last year of cancer drug maker Sierra Oncology and vaccine maker Affinivax for £1.5billion and £2.7billion respectively. ‘We are absolutely ...

Predictive Oncology Inc POAI

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Emma Walmsley

5mon ago, source: Fortune

Early in 2023, British pharma giant GSK launched the world’s first RSV adult vaccine, Arexvy, for those aged 60 years and older. Walmsley, the only woman CEO of a major pharma company, told ...

What's Going On With Elevation Oncology Stock?

2mon ago, source: Hosted on MSN

Elevation Oncology, Inc. (NASDAQ: ELEV) shares raced higher Monday. The company announced program updates and upcoming 2024 milestones on Friday. Here's a look at what's going on. The Details ...

Predictive Oncology Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...